EGFR and lung carcinoma: These findings support hypoxia targeting in EGFR mutant tumors in the EGFR inhibitor–naive and refractory settings, which is the potential value of clinical testing and use of VEGF inhibitors in combination with EGFR-TKIs, but not just lung cancer.